ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Analysis of drug-drug interactions between psychiatric drugs in spontaneous adverse drug reaction reports from EudraVigilance.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In psychiatric care, polypharmacy is common practice. The more drugs are used, the higher the likelihood of drug-drug interactions (DDI) and, consequently, the occurrence of adverse drug reactions (ADR). The aim of our study was to identify DDI between psychiatric drugs and to analyze their associated factors in spontaneous ADR reports contained in the European ADR database EudraVigilance. Out of 9287 ADR reports from EudraVigilance, 1811 reports with potential DDI (pDDI) were detected by the ABDATA interaction analysis. During the individual case assessment of the most frequently identified pDDI (n = 1342), 206 reports with DDI were found. These 206 reports were analyzed descriptively. Patients who experienced DDI were on average 52.6 (± 18.8) years old. Reports describing DDI were clearly more often classified as serious than those without DDI (81.1% versus 59.0%, p-value < 0.005). The DDI most frequently identified were tachycardia and QT prolongation (23.3%, 48/206), extrapyramidal symptoms (16.0%, 33/206), sedation (11.7%, 24/206) and seizures (11.7%, 24/206). Mirtazapine-quetiapine (26.3%, 10/48) was the interacting drug pair most commonly associated with tachycardia and QT prolongation. Patients experiencing tachycardia and QT prolongation were, on average, older (63.0 (± 16.2) years) and took more drugs (8.0 (± 5.3)) than the overall group of patients with DDI (6.0 (± 3.9)). DDI pose a considerable risk to patients treated with several combinations of psychiatric drugs. Checks for interactions and tight monitoring after initiating drug therapy can help to avoid serious DDI. Special attention should be paid to older patients taking more than one QT-interval prolonging drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.